Psoriasis Registry Austria (PsoRA)

Eine herausragende interdisziplinäre Kohorte des BBMRI.at-Partners Medizinische Universität Graz an der Biobank Graz

Das Psoriasis Registry Austria (PsoRA) wurde 2009 gegründet, um die Behandlung von Psoriasis-Patient in Österreich systematisch zu dokumentieren und kontinuierlich zu verbessern. Die von der Medizinischen Universität Graz in Zusammenarbeit mit der Österreichischen Gesellschaft für Dermatologie und Venerologie (ÖGDV) entwickelte webbasierte Datenbank ist in das europaweite Psoriasis-Register „Initiative PsoNet“ eingebettet.

 

PsoRA enthält detaillierte Informationen zur Behandlung von Psoriasis-Patient. Über viele Jahre hinweg wurden sämtliche angewandten Therapieoptionen, deren zeitliche Abfolge, Nebenwirkungen sowie Behandlungserfolge unter den Bedingungen der klinischen Routineversorgung dokumentiert. Gemessen an der Bevölkerungsgröße zählt diese österreichische Datenbank zu den größten ihrer Art weltweit.

Profil der Kohorte (auf Englisch)

Research Area
Improve therapy of patients with psoriasis in Austria under everyday conditions
• Therapy efficacy in clinical routine
• Therapy response
• Long-term therapy
• Therapy changes and side effects
Cohort Type
Human, observational, retrospective, cross-sectional
Cohort Size
• >2200 samples from >850 patients in >27.000 aliquots, from >350 patients >samples
• Collection ongoing
Biological Sample Types (with storage condition)
• Serum
• EDTA plasma
• Buffy coat
• PaxGene

Stored in Biobank Graz at -80°C
Associated Data
Base demographic
Psoriasis specific disease scores and treatment outcome
Concomitant medication
Concomitant diseases
Routine haematology results (including organ function ALAT, ASAT, GGT, LDH, CRK, …)
Donors Details
• 34.7% female : 65.3% male
• Median age 46,4 [18 – 82]
• Median BMI 27.4 [16.9 – 55.4]

Psoriasis patients scheduled for biologics treatment in Graz, sampled at different time points (naïve, 0-1M, 1-4 M, 4-8M, 8-16M, u003e16M after treatment)
Collection Period
2016 – ongoing
Informed Consent
Broad biobank consent & specific study IC
Access
Yes – collaboration only
Quality Standards
ISO 9001:2015 (Biobank Graz) for serum, EDTA sample aliquots
Contact
Principal investigators:
• Prof. Dr. Peter Wolf, peter.wolf@medunigraz.at
• Dr. Thomas Graier, thomas.graier@medunigraz.at
• Dr. Natalie Bordag, n.bordag@medunigraz.at
Publications (scientific)
List see below
Media articles
See below
Research projects
• Predictive biomarkers for therapeutic response
• Surrogate markers for systemic inflammation and co-morbidities 
Publikationen (wissenschaftlich):
  • Real-world evidence on palmoplantar pustulosis: patient characteristics, diagnostic challenges and predictive factors for treatment survival – a retrospective registry study. Graier T, et al, British Journal of Dermatology (BJD), 2026, 194(1): 77-85, doi: 1093/bjd/ljaf394

 

  • Predictors of treatment survival in patients with plaque psoriasis treated with phototherapy: registry analysis. Graier T, et al. Skin Health Dis. 2025 May 16;5(3):214-222. doi: 1093/skinhd/vzaf021

 

  • Psoriasis and its impact on close relatives and partners of patients – A cross-sectional questionnaire study. Grossschaedl K, et al. Skin Health Dis. 2024 Mar 15;4(3):e355. doi: 1002/ski2.355

 

  • Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004-2022. Graier T, et al. J Dtsch Dermatol Ges. 2023 Dec;21(12):1513-1523. doi: 1111/ddg.15213

 

  • Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). Graier T, et al. Sci Rep. 2022 Sep 5;12(1):15078. doi: 1038/s41598-022-18790-9

 

  • Furin Expression in Patients With Psoriasis-A Patient Cohort Endangered to SARS-COV2? Graier T, et al. Front Med (Lausanne). 2021 Feb 10;8:624462. doi: 3389/fmed.2021.624462.

 

  • Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Graier T, et al.  Br J Dermatol. 2021 Jun;184(6):1094-1105. doi: 1111/bjd.19701

 

  • Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis. Graier T, et al. JAAD Int. 2020 Dec 26;2:62-75. doi: 1016/j.jdin.2020.10.012

 

  • Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries. Busard CI, et al. J Eur Acad Dermatol Venereol. 2018 Feb;32(2):245-253. doi: 1111/jdv.14583

 

  • Survival and effectiveness of tumour necrosis factor-alpha inhibitors in the treatment of plaque psoriasis under daily Life conditions: report from the Psoriasis Registry Austria. Inzinger M, et al. Acta Derm Venereol. 2016 Feb;96(2):207-12. doi: 2340/00015555-2214

 

  • Patient perspectives on treating psoriasis with classic inpatient dithranol therapy: a retrospective patient survey. Painsi C, et al .J Dtsch Dermatol Ges. 2015 Nov;13(11):1156-63. doi: 1111/ddg.12820

 

  • Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions. Inzinger M, et al. J Eur Acad Dermatol Venereol. 2013 Jul;27(7):861-6. doi: 1111/j.1468-3083.2012.04596.x

 

  • Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Inzinger M, et al.Br J Dermatol. 2011 Sep;165(3):640-5. doi: 1111/j.1365-2133.2011.10396.x

 

Medienberichte:

 

 

 

Über PsoRA
Fünfzehn Jahre Psoriasis Registry Austria (PsoRA) – und es wird noch mehr werden